Floatz logo

Docetaxel

Male Reproductive Cancer

Small moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Male Reproductive Cancer cohort.

Asset / SponsorPhaseRating
HYPERICUM
Phase 3B
DARATUMUMAB
M.D. Anderson Cancer Center
Phase 2CCC
Olaparib
M.D. Anderson Cancer Center
Phase 1CC
Cord Blood-Derived Expanded Allogeneic Natural Killer Cells
M.D. Anderson Cancer Center
Phase 1CC
Valproic Acid
M.D. Anderson Cancer Center
Phase 1CC

View all 15 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →